Breakout Sessions: Preparing for New Product Introduction

10:00 AM - 11:00 AM
Room 146A

Following panel 1, there will be three separate breakout sessions. Each of these will explore strategies for the introduction of new interventions to developing world markets - one focusing on drugs, one on vaccines, and one on diagnostics. Panelists with on-the-ground experience will discuss key barriers to effective product introduction and key interventions at both the global and local levels to overcome these hurdles.

Focus: Vaccines

Panelists:

  • Moderator: Carol Marzetta, Chief Scientific Officer, Applied Strategies
  • Lewellys Barker, Senior Scientist, Aeras Global TB Vaccine Foundation
  • Mark Feinberg, Vice President, Medical Affairs and Policy, Merck Vaccines
  • Phil Hosbach, Vice President, Government Relations and Immunization Policy, Sanofi Pasteur
  • Lois Privor-Dumm, Director, International Vaccines Access Center (IVAC)

Who's Who


 

  Lewellys F. Barker - Lewellys F. Barker, MD, MPH, is currently Senior Medical Advisor at Aeras, a non-profit product development partnership based in  Rockville, Maryland, which is conducting R&D on new TB vaccines.  He served in the US Public Health Service as a medical research laboratory and clinical investigator and senior manager with the NIH Division of Biologics Standards and the US Food and Drug Administration Bureau of Biologics, and at the Division of AIDS of the US NIH/NIAID, with responsibilities for product development, regulation, and public health applications.  He also worked as a Senior Vice President at the American Red Cross with responsibility for the Red Cross blood program.   His major career activities have included preclinical and clinical research on viral (e.g., hepatitis, HIV, smallpox), rickettsial and bacterial (TB) vaccines, immune globulins and diagnostics for detection, treatment and prevention of infectious diseases.  He is a graduate of Princeton University and Johns Hopkins University School of Medicine and School of Public Health and trained in Internal Medicine at the Johns Hopkins Hospital and New York University/Bellevue Hospital. 
   
Feinberg Mark Feinberg - Mark Feinberg is Vice President and Chief Public Health and Science Officer, Merck Vaccines at Merck & Co., Inc., where he focuses on global efforts to implement vaccines and infectious disease therapies to achieve the greatest individual and public health benefits.  In this role, he is also responsible for developing initiatives and partnerships that accelerate the global availability of Merck's drugs and vaccines, and that enable Merck's R&D expertise to help address health challenges impacting resource-poor countries.  Prior to joining Merck in 2004, Dr. Feinberg worked for over 20 years in both academia and government where he was actively engaged in basic and clinical research, patient care and health care policy--with a primary focus on HIV/AIDS pathogenesis, treatment and prevention research.  Dr. Feinberg is a Fellow of the American College of Physicians, and a member of the Council on Foreign Relations and the Association of American
Physicians.  He is the recipient of an Elizabeth Glaser Scientist Award from the Pediatric AIDS Foundation and an Innovation in Clinical Research Award from the Doris Duke Charitable Foundation.  

Dr. Feinberg has also served as a member of several committees of the Institutes of Medicine and the National Academy of Sciences, and on the National Vaccine Advisory Committee (NVAC).  Dr. Feinberg currently serves as a member of the Institute of Medicine's Forum on Microbial Threats, the Board of Trustees of the National Foundation for Infectious Diseases (NFID), the Board of Directors for the African Comprehensive HIV/AIDS Partnerships (ACHAP) Program, the External Advisory Board of the HIV Vaccine Trial Network (HVTN), and the Scientific Advisory Board of the US President's Emergency Plan for AIDS Relief (PEPFAR).
   
 

Philip Hosbach - Philip Hosbach currently holds the position of Vice President of Immunization Policy and Government Relations at sanofi pasteur.  The departments under his supervision are state government affairs, federal government affairs, medical communications, strategic advocacy and immunization initiatives.  His responsibilities include oversight of both public policy and immunization policy development. Mr. Hosbach acts as sanofi pasteur’s principle liaison with CDC, and coordinated sanofi pasteur’s global efforts in responding to the emerging H1N1 pandemic.

He is a graduate of Lafayette College (1984) and began his professional career in the pharmaceutical industry with American Home Products.

That career has now spanned 27 years, including the last 24 years focused solely on vaccines. Mr. Hosbach joined sanofi pasteur (then Connaught Labs) in 1987 in Clinical Research and held positions of increasing responsibility, including Director of Clinical Operations. While in Clinical Research, he also served as Project Manager for the development and licensure of Tripedia, the first diphtheria, tetanus and acellular pertussis (DTaP) vaccine approved by FDA for use in US infants. During his clinical research career at sanofi pasteur, he contributed to the development and licensure of seven vaccines.

Following his work in clinical research Mr. Hosbach took a position in the commercial operations area of sanofi pasteur and took on positions of increasing responsibility on the business administration side of the vaccine division. During that time Mr. Hosbach led a number of departments within sanofi pasteur gaining valuable business experience within US Commercial Operations. The departments he led during that time included Public Health Sales and Marketing, Public Relations, Public Affairs, New Product Marketing and Business Intelligence.

He has been a member of the Institute of Medicine’s Forum on Microbial Threats since 2005 and has been a Steering Committee member on the National Influenza Vaccine Summit since its inception. Since 2000 Mr. Hosbach has served on the Board of Directors for Pocono Medical Center and Pocono Health Systems, located in East Stroudsburg, PA. He currently serves Chairman of the Compensation Committee.

   
Marzetta Carol Marzetta - Dr. Marzetta is chief scientific officer and co-founder of Applied Strategies, a management consulting firm dedicated to bridging the discoveries of life sciences and the needs of global health.

She has been integral to the company’s work in helping the global health community forecast vaccine supply and demand, assess the value and risk to suppliers and donors of global markets, and understand the potential impact of new product introduction, both individually and across a portfolio of new products and interventions.  She has led projects assessing new technology critical path and health impact, conducting global market characterization and value assessments, and supporting public-private partnerships.

Dr. Marzetta has over 15 years of leadership experience in small molecule and biologic drug development in both global pharmaceutical and emerging biotechnology companies and over 8 years in global health.  Her broad experience spans drug discovery, preclinical and clinical development.  She now brings her global biopharmaceutical and global health experience together to find solutions that bring private industry and global health partners together to accelerate the introduction of medicines and vaccines into developing countries.
   
  Lois Privor-Dumm - Ms. Privor-Dumm heads up the Alliances and Information Team at IVAC, which includes advocacy and communications, World Pneumonia Day Coalition coordination and advocacy activities and Large Country Introduction, providing cross-cutting support for new vaccine decision making for India and Nigeria for the Accelerated Vaccine Initiative Technical Assistance Consortium (AVI TAC).  Previously, she was Director, Access and Implementation for the PneumoADIP and Director, Communications and Strategy for the Hib Initiative, both based at Johns Hopkins. She came to Johns Hopkins in 2005, after spending nearly two decades working in various industry positions with Wyeth, GlaxoSmithKline and Pfizer.  Notably, she led a team that launched Prevnar,® pneumococcal conjugate vaccine in the US and as Commercial Director in Latin America and Sr. Commercial Director, Europe, Middle East and Africa, supported additional launches and commercial operations for both Wyeth’s pharmaceutical and biologicals businesses.  She has worked in various functions including marketing, operations, strategy, commercial development, policy, market research, forecasting, auditing and finance.  She holds a Master’s degree in International Business Studies from the University of South Carolina and completed her studies and internship in Belgium and a Bachelor of Science from the State University of New York at Albany where she double majored in Business Administration (finance) and Spanish.